Cargando…

Sodium glucose co-transporter 2 inhibitors mediated ketogenesis in patients with metabolic syndrome: clear benefit or anticipated fear?

Detalles Bibliográficos
Autor principal:	Patoulias, Dimitrios Ioannis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2019
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451140/ https://www.ncbi.nlm.nih.gov/pubmed/30963130 http://dx.doi.org/10.5114/amsad.2019.83302

Ejemplares similares

Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis
por: Kalra, Sanjay, et al.
Publicado: (2015)

Time to assess the effects of sodium–glucose co‐transporter‐2 inhibitors on the ‘forgotten' right ventricle?
por: Patoulias, Dimitrios, et al.
Publicado: (2019)

Sodium-glucose co-transporter-2 inhibitor mediated cardio-protection: does increase of hematocrit finally matter? Sub-analysis of a prospective, observational study
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Sodium-glucose co-transporter-2 inhibitors in the intensive care unit setting: Do we really need sodium increase, especially in sepsis?
por: Patoulias, Dimitrios
Publicado: (2023)

Surrogate cardiovascular outcomes with sodium-glucose co-transporter-2 inhibitors in women: An updated meta-analysis
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Is there a distinct phenotype of diabetic patients who benefit from tofogliflozin?
por: Patoulias, Dimitrios Ioannis
Publicado: (2018)

The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors
por: Ito, Marie, et al.
Publicado: (2018)

Harms and benefits of sodium-glucose co-transporter 2 inhibitors
por: Chesterman, Thomas, et al.
Publicado: (2020)

Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors
por: Vargas-Delgado, Ariana P., et al.
Publicado: (2023)

Mitochondria-Mediated Cardiovascular Benefits of Sodium-Glucose Co-Transporter 2 Inhibitors
por: Dabravolski, Siarhei A., et al.
Publicado: (2022)

Meta-analysis addressing the impact of sodium-glucose Co-transporter-2 inhibitors on the risk for atrial fibrillation among individuals with heart failure with preserved ejection fraction
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Sodium Glucose Co-transporter-2 Inhibitor: Benefits beyond Glycemic Control
por: Baruah, Manash Pratim, et al.
Publicado: (2019)

Sodium glucose co transporter 2 inhibitors and Ramadan: Another string to the bow
por: Kelwade, Jayant, et al.
Publicado: (2014)

Therapeutic versus prophylactic heparin for thromboprophylaxis in patients with COVID-19: weighing the costs and benefits. A rapid meta-analysis of randomized controlled trials
por: Dimosiari, Athina, et al.
Publicado: (2022)

Effect of withholding early parenteral nutrition in PICU on ketogenesis as potential mediator of its outcome benefit
por: De Bruyn, Astrid, et al.
Publicado: (2020)

miRNA-122: Can it unravel an alternative pathway in early diagnosis and prognosis of type 2 diabetes mellitus?
por: Patoulias, Dimitrios Ioannis
Publicado: (2018)

Canakinumab: can it untie the Gordian knot of cardiovascular disease in patients with familial Mediterranean fever?
por: Patoulias, Dimitrios Ioannis
Publicado: (2018)

Sexual dysfunction among women with systemic lupus erythematosus: might it reflect cardiovascular disease burden?
por: Patoulias, Dimitrios Ioannis
Publicado: (2019)

Serum chemerin in patients with rheumatoid arthritis: can it unravel the Chimera of concomitant type 2 diabetes?
por: Patoulias, Dimitrios Ioannis
Publicado: (2020)

Liraglutide for non-alcoholic fatty liver disease in children and adolescents: has a new era arrived?
por: Patoulias, Dimitrios Ioannis
Publicado: (2019)

Non-alcoholic fatty liver disease in patients with inflammatory bowel disease might boost cardiovascular disease burden
por: Patoulias, Dimitrios Ioannis
Publicado: (2019)

Sodium–Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions
por: Patoulias, Dimitrios, et al.
Publicado: (2020)

Impaired ketogenesis ties metabolism to T cell dysfunction in COVID-19
por: Karagiannis, Fotios, et al.
Publicado: (2022)

Fournier's Gangrene and Sodium-glucose Co-transporter 2(SGLT2) Inhibitors: Our Experience
por: Dass, Ashwitha S., et al.
Publicado: (2019)

Dietary-Induced Ketogenesis: Adults Are Not Children
por: Porper, Keren, et al.
Publicado: (2021)

Does a gluten-free diet determine the efficacy of sotagliflozin in patients with concomitant type 1 diabetes mellitus and celiac disease?
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2018)

Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2021)

Ketogenesis impact on liver metabolism revealed by proteomics of lysine β-hydroxybutyrylation
por: Koronowski, Kevin B., et al.
Publicado: (2021)

Association between Impaired Ketogenesis and Metabolic-Associated Fatty Liver Disease
por: Bae, Jaehyun, et al.
Publicado: (2023)

Hepatitis C virus infection and atherosclerotic cardiovascular disease: recent knowledge, further insights
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2020)

Lean non-alcoholic fatty liver disease: do not forget diabetes
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2019)

Use of Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetics: Are the Benefits Worth the Risks?
por: Fatima, Tehreem, et al.
Publicado: (2020)

Sodium-glucose co-transporter 2 inhibitors induced euglycemic diabetic ketoacidosis within four days of initiation
por: Razok, Almurtada, et al.
Publicado: (2022)

Euglycemic diabetic ketoacidosis: A rare but serious side effect of sodium-glucose co-transporter 2 inhibitors
por: Lakušić, Nenad, et al.
Publicado: (2022)

LOCALIZATION OF THE ENZYMES OF KETOGENESIS IN RAT LIVER MITOCHONDRIA
por: Chapman, M. John, et al.
Publicado: (1973)

Meckel’s diverticulum complications in three first-degree relatives: time to rethink familial predisposition?
por: Patoulias, Ioannis, et al.
Publicado: (2020)

Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Bone Metabolism and Fracture Risk
por: Ye, Yangli, et al.
Publicado: (2019)

Exploration of the clinical benefits of sodium glucose co-transporter 2 inhibitors in diabetic patients with concomitant heart failure
por: Tanaka, Atsushi, et al.
Publicado: (2018)

Benefits/Risks of Sodium–Glucose Co-Transporter 2 Inhibitor Canagliflozin in Women for the Treatment of Type 2 Diabetes
por: Kushner, Pamela
Publicado: (2016)

Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Sodium–Glucose Co-transporter-2 Inhibitors
por: Neumiller, Joshua J, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1ifvoum70f9d56hrmssou2plsv